Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$1.0 - $1.47 $56,500 - $83,055
-56,500 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$1.09 - $2.21 $1.5 Million - $3.04 Million
-1,376,164 Reduced 96.06%
56,500 $62,000
Q4 2019

Feb 14, 2020

BUY
$0.71 - $4.91 $1.02 Million - $7.03 Million
1,432,664 New
1,432,664 $6.42 Million

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $331M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Eco R1 Capital, LLC Portfolio

Follow Eco R1 Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.